10 / 74 · 1:01 · Original AXON film
Cerebrolysin
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
CEREBROLYSIN | Human trial evidence
For stroke research, the outcome you measure can change the headline. Cerebrolysin is a peptide mixture studied as an additional treatment. [1] [2]
COCHRANE 2023 | Benefit and safety limits
A 2023 Cochrane review found no convincing survival benefit and a possible increase in nonfatal serious adverse events. Those findings deserve attention. [1]
LATER REVIEW | Different endpoints
A later review reported improvement in early neurological scores. Different trial selections and endpoints help explain why the summaries differ; they do not settle every recovery question. [2]
Clinical context matters
Cerebrolysin is not FDA-approved in the United States. It should never be presented as a replacement for urgent stroke care or evidence-based rehabilitation. [3] [1]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Cerebrolysin for acute ischaemic stroke: 2023 Cochrane review →Authoritative systematic review of randomized human trials
- Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: Meta-Analysis of 14 RCTs →Later peer-reviewed systematic review; different inclusion criteria and outcomes
- Cerebrolysin official product site: US regulatory disclosure →Manufacturer used only for explicit US nonapproval disclosure, not efficacy claims
